You are here

Safety Study of Ointment for the Treatment of Plaque-type Psoriasis

Last updated on March 22, 2018

FOR MORE INFORMATION
Study Location
CMAX (A Division of IDT Australia Ltd)
Adelaide, , 5000 Australia
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Plaque-type Psoriasis
Sex
Male
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-55 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- White males, 18 - 55 years (inclusive) of age at the time of randomization.

- Body weight between 60-90 kg (Body Mass Index [BMI] between 19 and 30 kg/m2
[inclusive]).

- Willing and able to comply with study instructions and commit to all follow-up visits.

- Have adequate venous access to permit repeated PK sampling.

- Ability to understand, agree to and sign the study Informed Consent Form (ICF) prior
to initiation of any protocol-related procedures.

- Non-smokers (refrained from any tobacco usage, including smokeless tobacco, nicotine
patches, etc., for 6 months prior to the administration of the study medication).

For psoriasis patients (in addition to the above criteria):

- Clinical diagnosis of stable plaque-type psoriasis with active plaques involving
5%-20% of total BSA excluding face, scalp and groin.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- History of serious adverse reactions or hypersensitivity to any drug; or known allergy
to any of the test product(s) or any components in the test product(s) or history of
hypersensitivity; or allergic reactions to any of the study preparations as described
in the Investigator's Brochure.

- Any clinically significant central nervous system (e.g., seizures), cardiac,
pulmonary, metabolic, renal, hepatic or gastrointestinal conditions or history of such
conditions that, in the opinion of the Investigator may place the subject at an
unacceptable risk as a participant in this trial or may interfere with the
distribution, metabolism or excretion of drugs.

- Abnormal physical findings of clinical significance at the Screening examination or
Baseline which would interfere with the objectives of the study.

- History of orthostatic hypotension (an increase in HR ?20 bpm accompanied by a ?20 mm
Hg drop in SBP and/or ?10 mm Hg drop in DBP) present at Screening.

- Clinically significant abnormal laboratory values (as determined by the Investigator)
at the Screening evaluation.

- Presence or history of allergies requiring acute or chronic treatment (except seasonal
allergic rhinitis).

- 12-lead ECG obtained at Screening with: PR >240 msec, QRS >110 msec and QTc >450 msec,
bradycardia ( ECG, or any other changes on the Screening ECG that would interfere with measurement
of the QT interval.

- Major surgical interventions within 6 months of the study.

- Has a positive pre-study Hepatitis B surface antigen; positive Hepatitis C (HCV)
antibody or detectable HCV ribonucleic acid (RNA); or positive HIV antibody result.

- Use of prescription or non-prescription drugs, including vitamin supplements, herbal
and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to
the first dose of study medication, or use of St. John's Wort within 28 days prior to
the first dose of study medication. However, the Investigator and study team can
review medication use on a case by case basis to determine if its use would compromise
subject safety or interfere with study procedures or data interpretation. By
exception, the subject may take paracetamol or acetaminophen (?2 g/day) or ibuprofen
(?1600 mg/day) up to 48 h prior to the first dose of study medication.

- Has a history of regular alcohol consumption averaging >14 drinks/week (1 drink [100
mL wine or 280 mL standard strength beer or 30 mL of 80 proof distilled spirits])
within 6 months of the Screening visit.

- Loss of 500 mL blood or more during the 3 month period before the study, e.g., blood
donor.

- People that follow vegetarian or vegan diets.

- Symptoms of a significant somatic or mental illness in the four week period preceding
drug administration.

- History of drug abuse or dependence within 12 months of the study.

- Positive pre-study urine drug and alcohol screen. A minimum list of drugs that will be
screened for include benzodiazepines, opiates, methadone metabolite (EDDP),
sympathomimetic amines, cannabinoids, barbiturates, cocaine, and ethanol. (Suspected
false positive results may be repeated at the discretion of the Investigator.)

- Concurrent or recent (within 60 days) participation in another drug or device research
study.

- Considered by the Investigator to be unsuitable candidate for this study. Use of
AN2728 in a previous clinical trial.

For psoriasis patients (in addition to the above exclusion criteria):

- Spontaneously improving or rapidly deteriorating psoriatic plaques or
pustular/exfoliative, guttate, erythrodermic or other non-plaque form of psoriasis.

- Currently have drug-induced psoriasis (new onset or exacerbation of psoriasis from
beta blockers, calcium channel blockers, or lithium).

- Other serious skin disorder(s).

- Use of non-biologic systemic anti-psoriatic therapy (e.g., corticosteroids, PUVA, UVB,
retinoids, methotrexate, cyclosporine, other immunosuppressive agents) or biologic
therapy (e.g., alefacept, etanercept, adalimumab, ustekinumab) within four weeks prior
to enrollment or concurrently during the study.

- Use of topical treatments that have a known beneficial effect on psoriasis, including
but not limited to corticosteroids, retinoids, vitamin D derivatives, tar or
anthralin, within the past two weeks prior to enrollment or concurrently during the
study.

- Systemic medications for other medical conditions that are known to affect psoriasis
(e.g., lithium, beta adrenergic blockers) within the past four weeks prior to
enrollment or concurrently during the study.

- Use of emollients/moisturizers on area(s) to be treated within two days prior to
enrollment.

NCT01258088
Pfizer
Completed
Safety Study of Ointment for the Treatment of Plaque-type Psoriasis

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Safety Study of Ointment for the Treatment of Plaque-type Psoriasis
A Randomized, Double-Blind, Vehicle-Controlled, Multiple Cohort Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of AN2728 Ointment B, 2% in Healthy Volunteers and Patients With Mild-to-Moderate Plaque-Type Psoriasis
The purpose of this study is to determine how much drug is absorbed throughout the body after being applied to the skin.
Not Provided
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Plaque-Type Psoriasis
  • Drug: AN2728 Ointment
    5mg/cm2, BID
  • Drug: AN2728 Vehicle
    5mg/cm2 BID
  • Active Comparator: Cohort 1: AN2728 Ointment
    Intervention: Drug: AN2728 Ointment
  • Placebo Comparator: Cohort 1: AN2728 Vehicle
    Intervention: Drug: AN2728 Vehicle
  • Active Comparator: Cohort 3: AN2728 Ointment
    Intervention: Drug: AN2728 Ointment
  • Placebo Comparator: Cohort 3: AN2728 Vehicle
    Intervention: Drug: AN2728 Vehicle
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
16
December 2010
December 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • White males, 18 - 55 years (inclusive) of age at the time of randomization.
  • Body weight between 60-90 kg (Body Mass Index [BMI] between 19 and 30 kg/m2 [inclusive]).
  • Willing and able to comply with study instructions and commit to all follow-up visits.
  • Have adequate venous access to permit repeated PK sampling.
  • Ability to understand, agree to and sign the study Informed Consent Form (ICF) prior to initiation of any protocol-related procedures.
  • Non-smokers (refrained from any tobacco usage, including smokeless tobacco, nicotine patches, etc., for 6 months prior to the administration of the study medication).

For psoriasis patients (in addition to the above criteria):

  • Clinical diagnosis of stable plaque-type psoriasis with active plaques involving 5%-20% of total BSA excluding face, scalp and groin.

Exclusion Criteria:

  • History of serious adverse reactions or hypersensitivity to any drug; or known allergy to any of the test product(s) or any components in the test product(s) or history of hypersensitivity; or allergic reactions to any of the study preparations as described in the Investigator's Brochure.
  • Any clinically significant central nervous system (e.g., seizures), cardiac, pulmonary, metabolic, renal, hepatic or gastrointestinal conditions or history of such conditions that, in the opinion of the Investigator may place the subject at an unacceptable risk as a participant in this trial or may interfere with the distribution, metabolism or excretion of drugs.
  • Abnormal physical findings of clinical significance at the Screening examination or Baseline which would interfere with the objectives of the study.
  • History of orthostatic hypotension (an increase in HR ?20 bpm accompanied by a ?20 mm Hg drop in SBP and/or ?10 mm Hg drop in DBP) present at Screening.
  • Clinically significant abnormal laboratory values (as determined by the Investigator) at the Screening evaluation.
  • Presence or history of allergies requiring acute or chronic treatment (except seasonal allergic rhinitis).
  • 12-lead ECG obtained at Screening with: PR >240 msec, QRS >110 msec and QTc >450 msec, bradycardia (<50 bpm) or clinically significant minor ST wave changes on the Screening ECG, or any other changes on the Screening ECG that would interfere with measurement of the QT interval.
  • Major surgical interventions within 6 months of the study.
  • Has a positive pre-study Hepatitis B surface antigen; positive Hepatitis C (HCV) antibody or detectable HCV ribonucleic acid (RNA); or positive HIV antibody result.
  • Use of prescription or non-prescription drugs, including vitamin supplements, herbal and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication, or use of St. John's Wort within 28 days prior to the first dose of study medication. However, the Investigator and study team can review medication use on a case by case basis to determine if its use would compromise subject safety or interfere with study procedures or data interpretation. By exception, the subject may take paracetamol or acetaminophen (?2 g/day) or ibuprofen (?1600 mg/day) up to 48 h prior to the first dose of study medication.
  • Has a history of regular alcohol consumption averaging >14 drinks/week (1 drink [100 mL wine or 280 mL standard strength beer or 30 mL of 80 proof distilled spirits]) within 6 months of the Screening visit.
  • Loss of 500 mL blood or more during the 3 month period before the study, e.g., blood donor.
  • People that follow vegetarian or vegan diets.
  • Symptoms of a significant somatic or mental illness in the four week period preceding drug administration.
  • History of drug abuse or dependence within 12 months of the study.
  • Positive pre-study urine drug and alcohol screen. A minimum list of drugs that will be screened for include benzodiazepines, opiates, methadone metabolite (EDDP), sympathomimetic amines, cannabinoids, barbiturates, cocaine, and ethanol. (Suspected false positive results may be repeated at the discretion of the Investigator.)
  • Concurrent or recent (within 60 days) participation in another drug or device research study.
  • Considered by the Investigator to be unsuitable candidate for this study. Use of AN2728 in a previous clinical trial.

For psoriasis patients (in addition to the above exclusion criteria):

  • Spontaneously improving or rapidly deteriorating psoriatic plaques or pustular/exfoliative, guttate, erythrodermic or other non-plaque form of psoriasis.
  • Currently have drug-induced psoriasis (new onset or exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium).
  • Other serious skin disorder(s).
  • Use of non-biologic systemic anti-psoriatic therapy (e.g., corticosteroids, PUVA, UVB, retinoids, methotrexate, cyclosporine, other immunosuppressive agents) or biologic therapy (e.g., alefacept, etanercept, adalimumab, ustekinumab) within four weeks prior to enrollment or concurrently during the study.
  • Use of topical treatments that have a known beneficial effect on psoriasis, including but not limited to corticosteroids, retinoids, vitamin D derivatives, tar or anthralin, within the past two weeks prior to enrollment or concurrently during the study.
  • Systemic medications for other medical conditions that are known to affect psoriasis (e.g., lithium, beta adrenergic blockers) within the past four weeks prior to enrollment or concurrently during the study.
  • Use of emollients/moisturizers on area(s) to be treated within two days prior to enrollment.
Sexes Eligible for Study: Male
18 Years to 55 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
Australia
 
 
NCT01258088
AN2728-PSR-104
Yes
Not Provided
Not Provided
Lee Zane, MD, MAS, Anacor Pharmaceuticals, Inc
Pfizer
Not Provided
Principal Investigator: Sepehr Shakib, MB BS, PhD Royal Adelaide Hospital
Pfizer
December 2010

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now